Results 161 to 170 of about 46,553 (219)

Chronic Inflammatory Demyelinating Polyneuropathy

open access: yes, 2019
Chronic inflammatory demyelinating polyneuropathy (CIDP) is immune-mediated neuropathy defined by clinical progression for more than 2 months, and electrodiagnostic evidence of peripheral nerve demyelination. However, there are several clinical phenotypes, classified into "typical CIDP," and "atypical CIDP" such as "multifocal acquired demyelinating ...
Satoshi, Kuwabara, Sonoko, Misawa
openaire   +3 more sources

[Chronic inflammatory demyelinating polyneuropathy].

open access: yesUgeskrift for laeger, 2020
In this review, we discuss chronic inflammatory demyelinating polyneuropathy (CIDP), which is a disease with proximal and distal weakness and sensory disturbances resulting in impaired daily activity. The diagnosis is based on the clinical presentation and electrophysiology demonstrating demyelination in the peripheral nerves.
Markvardsen, Lars Kjøbsted   +8 more
openaire   +3 more sources

"Minimal" chronic inflammatory demyelinating polyneuropathy

open access: yes, 1997
-
DI MUZIO, ANTONIO   +4 more
core   +4 more sources

Nerve ultrasound can distinguish chronic inflammatory demyelinating polyneuropathy from demyelinating diabetic sensorimotor polyneuropathy

open access: yesJournal of Clinical Neuroscience, 2018
Diabetic patients with poor glycaemic control can demonstrate demyelinating distal sensorimotor polyneuropathy (D-DSP) on electrophysiology. Distinguishing D-DSP from chronic inflammatory demyelinating polyneuropathy (CIDP) can be challenging.
Khean Jin Goh   +2 more
exaly   +4 more sources

Nerve root hypertrophy in chronic inflammatory demyelinating polyneuropathy

open access: yesMuscle and Nerve, 1994
A patient with chronic inflammatory demyelinating polyneuropathy (CIDP) and central demyelinating disease is described in whom striking nodular filling defects on multiple lumbar-sacral nerve roots, mimicking neurofibromata, were observed at myelography ...
Donald M Hadley, A I Weir
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Chronic Inflammatory Demyelinating Polyneuropathy

New England Journal of Medicine, 2005
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disease of the peripheral nervous system with a prevalence of 1-2/100,000. Clinical and experimental findings suggest a role of immune pathomechanisms;however, the target antigens are still unknown.
Hubertus, Köller   +3 more
openaire   +3 more sources

Chronic inflammatory demyelinating polyneuropathy

Current Treatment Options in Neurology, 2003
Although there are close to 10 randomized trials showing efficacy for prednisone, intravenous immunoglobulin, or plasmapheresis in chronic inflammatory demyelinating polyneuropathy (CIDP), large differences in cost, side effect profiles, and ease of use create controversy over the therapy that is best.
Jonathan S., Katz, David S., Saperstein
openaire   +2 more sources

Chronic Demyelinating Polyneuropathies

Continuum, 2017
This article reviews the chronic demyelinating neuropathies, with a focus on the diagnosis and treatment of immune-mediated neuropathies and the features that can help differentiate immune-mediated neuropathies from other chronic demyelinating peripheral nerve conditions.Advances in clinical phenotyping and outcomes assessment have enabled neurologists
openaire   +2 more sources

Electrophysiology in demyelinating polyneuropathies

Expert Review of Neurotherapeutics, 2008
Demyelinating neuropathies are disorders of the peripheral nervous system in which the myelin sheath of axons is affected by immune-mediated or genetically determined processes. In single axons, demyelination yields conduction block due to extinction of action potentials or conduction slowing.
openaire   +2 more sources

Treatment of chronic inflammatory demyelinating polyneuropathy

Muscle & Nerve, 2022
AbstractChronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic peripheral polyneuropathy that results in disability through immune‐mediated nerve injury, but which not uncommonly has residual and irreversible neurological deficits after the active inflammatory component of the disorder has been treated.
Jeffrey A. Allen, Richard A. Lewis
openaire   +2 more sources

Home - About - Disclaimer - Privacy